Bristol-Myers Squibb Co Earnings - Q2 2026 Analysis & Highlights
Bristol-Myers Squibb reported strong Q2 2026 results driven by growth portfolio momentum, pipeline advancement, and disciplined execution, with raised full-year guidance reflecting confidence in near-term catalysts and long-term value creation.
Key Financial Results
Total revenue increased 5% year-over-year to approximately $13 billion in Q2 2026, with strong growth portfolio performance offsetting legacy portfolio decline.
Growth portfolio revenue rose 14% to $7.6 billion, now representing nearly 60% of total revenue.
Gross margin was 71.4% in Q2 2026, reflecting product mix.
Operating expenses were $4.1 billion for the quarter, with continued benefits from strategic productivity initiatives.
Diluted earnings per share were $2.04 for the quarter.
Operating cash flow of approximately $3.4 billion was generated in Q2, with an additional $1.2 billion in debt paid down.
Business Segment Results
Oncology segment: Qvantig delivered $261 million in revenue and is now annualizing at over $1 billion with 15% market share; Opdivo revenue decreased 4% to approximately $2.5 billion, primarily driven by conversion to Qvantig in the US; Opdualag delivered strong double-digit growth.
Hematology segment: Reblozyl grew 29% reflecting solid uptake in first-line MDS associated anemia; Breyanzi posted 41% growth driven by best-in-class profile and strong demand across approved indications.
Cardiovascular immunology segment: Eliquis revenue was approximately $4.5 billion, up 21% driven by strong demand through continued market share gains; Camzyos revenues increased 59% to $416 million.
Immunology segment: Sotyktu global revenue grew 23%.
Neuroscience segment: Qvantig grew 81% to $63 million in revenue, reflecting continued steady progress in the schizophrenia market.
Capital Allocation
Cash position of approximately $11.5 billion in cash equivalents and marketable securities as of June 30, 2026.
Dividend commitment continues as part of strategic and balanced approach to deploying strong cash flows.
Business development remains a priority, with regular evaluation of opportunities in therapeutic areas the company knows well.
Debt reduction of $1.2 billion in Q2 2026 demonstrates commitment to strengthening balance sheet.
Industry Trends and Dynamics
Multiple myeloma market: 70% to 80% of patients are treated in the community setting, creating opportunity for oral treatment options with manageable toxicity profiles.
Atrial fibrillation market: Approximately 10 million patients diagnosed and treated in the US, with roughly 40% of patients who should be anticoagulated remaining undertreated, largely driven by physician concerns around bleeding risk.
Idiopathic pulmonary fibrosis (IPF) market: Currently a roughly $4 billion market expected to grow significantly with improved treatments, potentially doubling to $8 billion to $10 billion by the middle of the 2030s.
Lupus market: A disease affecting millions of patients with very limited treatment options.
Competitive Landscape
Eliquis market position: New to brand share is approaching 80% in the US, with continued market share gains despite price decreases implemented at the start of the year.
Opdualag competitive position: Continues as leading standard of care and first-line melanoma treatment in the US.
IPF competitive dynamics: JASCAYD's strong launch validates market opportunity and demonstrates potential to gain significant share as better tolerated and effective new treatment options emerge; over 50% of new JASCAYD starts are coming after generic OFEV or generic Esbriet as switch or add-on treatments.
Milvexian differentiation: Designed to demonstrate superior bleeding profile compared to Eliquis with comparable efficacy, targeting patients with bleeding liability risk factors.
Macroeconomic Environment
Foreign exchange impact: Comparisons exclude the impact of foreign exchange, with US second half Eliquis sales expected to benefit from elimination of accumulated CPI penalty in certain government channels.
Growth Opportunities and Strategies
CELMoD platform expansion: Iberdomide awaiting August 17 PDUFA date as potential first commercialized CELMoD; Mezigdomide has PDUFA date of May 13, 2027; Golcadomide upcoming readouts with opportunity to revolutionize first-line LBCL and play significant role in second-line follicular lymphoma.
Pipeline advancement: Potential to introduce more than 10 new medicines by the end of the decade, with over 30 meaningful life cycle management opportunities during the same period.
Near-term pipeline milestones: Admilparant for pulmonary fibrosis, Arlo-cel for relapse or refractory multiple myeloma, Iberdomide progression-free survival data, Milvexian for secondary stroke prevention, RYZ101 in GEP-NETs, and Sotyktu in lupus expected to read out by end of 2026.
AI and technology integration: Partnership agreements with Anthropic and Nvidia to help scientists understand disease biology more deeply, design and test candidate molecules faster, and make earlier, better-informed decisions about which programs to move forward.
Cobenfy label expansion: Significant upside expected from future label expansions beyond approved schizophrenia indication, with Phase 3 BALSAM 1 and 2 studies in Bipolar-I disorder anticipated to read out in first half of 2027.
Admilparant positioning: Expected to play meaningful role in both IPF and PPF with improved efficacy and tolerability profile, with potential to be foundational as first branded option with versatility of being used in combination.
Financial Guidance and Outlook
Full-year 2026 revenue and adjusted EPS guidance increased based on strong first half results and current projections for balance of year.
Eliquis revenue growth projected at 20% to 25% for full year 2026.
Total legacy portfolio revenue decrease projected between 4% and 6% for full year 2026.
Gross margin, other income and expense, and tax rate projections maintained at previous levels.
Operating expenses slightly increased to account for accelerated prelaunch activities supporting CELMoDs (Iberdomide and Mezigdomide), expanding Pumitamig development program, and opportunities to further support growth portfolio.
Milvexian Atrial Fibrillation study readout expected in first quarter of 2027, shifted from late 2026 due to pace of events.
Cobenfy ADEPT program top-line data readouts anticipated to begin in early 2027 and be spread across the year, with potential interim analysis for ADEPT 1 later in 2026.
Eliquis loss of exclusivity in April 2028 lines up with filing and launch timelines of Milvexian.
Expected $1.5 to $2 billion step down in Eliquis sales in 2027 due to patent expiry in Europe in mid Q4 2026, offset by continued US sales.
Pipeline and Clinical Development
ASCO June 2026 presentations: Positive Phase 3 data from Mezigdomide SUCCESSOR-2 study showed statistically significant and clinically meaningful improvement in progression-free survival for relapse or refractory multiple myeloma.
Solid tumor programs: Encouraging Phase 3 data from two iza-bren studies supporting differentiated ADC capabilities; fourth global Phase 3 study initiating in first-line EGFR mutant non-small cell lung cancer.
Pumitamig development: Encouraging early Phase 2 global data in combination with chemotherapy for first-line non-small cell lung cancer; new Phase 2 study combining Pumitamig with imzokitug (CCR8 antibody) initiating.
Admilparant mechanism: LPA1 is novel target working on fibrotic and inflammatory pathway as well as potentially on epithelium repair pathway; Phase 3 studies testing two doses (60 milligram and 120 milligrams) with IPF readout expected by end of 2026 and PPF readout a few months after.
Cobenfy in Alzheimer's psychosis: Slower pace of psychotic relapses in ADEPT 1 than predicted; quality prioritized in ADEPT 2 and ADEPT 4 to ensure highest chance of success; open-label data from ADEPT 1 and rollover ADEPT 3 data expected later in 2026.
Milvexian study design: Study designed to demonstrate non-inferiority on primary endpoint (stroke and systemic embolisms) with superiority on secondary endpoint (bleedings); requires 430 events for primary endpoint and 530 events for bleedings before database lock.
Moponitat (anti-tau antibody): Best-in-class potential with specific binding to R1 and R3 domains in microtubule binding region; Phase 2 recruitment completed with readout expected next year assessing tau clearance and cognition-related endpoints.
Operational and Strategic Initiatives
Productivity initiatives: Strategic productivity initiative continues to generate meaningful savings and provides flexibility to invest in growth-oriented opportunities.
Organizational evolution: Company rewiring into more agile, focused, and efficient organization with expanded use of AI across research and enterprise operations.
Study conduct improvements: Identified potential risks in ongoing studies and implemented mitigation measures; integrating AI technology, data, and other tools to improve probability of success in registration studies.
Cobenfy market education: Educational efforts ongoing to optimize dosing with focus on rapid titration to therapeutic dose of 125 milligrams; Phase 4 switch study introduced to help maximize efficacy.
